MTPAP

MTPAP (PAPD1/mtPAP) is a noncanonical poly(A) polymerase that polyadenylates mitochondrially encoded mRNAs to support their stability and translation (PMID:31779033). Structural and biochemical work established that it is catalytically active only as a homodimer: an N-terminal RNP-type RNA-binding fold (the RL domain) together with a β-arm insertion in the palm domain mediates dimerization, and dimerization is obligatory for activity (PMID:21292163). High-resolution structures further defined the basis for selective ATP incorporation and revealed an RNA-recognition module assembled by strand complementation across the dimer interface, while structurally explaining how the SPAX4-causing N478D substitution shortens mitochondrial poly(A) tails (PMID:26319014). Loss-of-function mutations truncate poly(A) tails on mitochondrial transcripts and impair de novo mitochondrial protein synthesis in patient fibroblasts (PMID:31779033), and a homozygous pathogenic mutation produces cellular radiosensitivity with delayed double-strand break repair, elevated ROS, and increased apoptosis that is rescued by wild-type cDNA and by antioxidant treatment, linking MTPAP dysfunction to ROS dysregulation (PMID:24651433). Pathogenic MTPAP mutations cause the neurodegenerative disorder SPAX4 (PMID:26319014).

1. 2011 High

   The unknown question of how MTPAP achieves catalysis was answered by showing it is an obligate homodimer with a defined active site formed at the palm-fingers interface.

   Evidence X-ray crystallography of human PAPD1 with active-site mutagenesis and in vitro activity assays

   PMID:21292163

   Open questions at the time

   • Does not establish RNA substrate specificity in vivo
   • Mechanism of substrate selection within the binding pocket not resolved
2. 2015 High

   It was unclear how MTPAP discriminates ATP and how disease mutations impair function; structures revealed the basis for ATP selectivity and a dimer-interface RNA-recognition module, and explained the N478D SPAX4 mutation as shortening poly(A) tails.

   Evidence High-resolution crystal structures including structural analysis of the disease-associated mutant

   PMID:26319014

   Open questions at the time

   • Structural snapshot does not capture catalytic cycle dynamics
   • Does not directly measure tail-length effects in patient tissue
3. 2014 Medium

   The pathogenic mechanism downstream of MTPAP loss was addressed by linking deficiency to ROS-driven radiosensitivity and impaired DNA double-strand break repair, with antioxidant rescue identifying ROS dysregulation as causal.

   Evidence Wild-type cDNA complementation, clonogenic survival, γH2AX foci, ROS measurement, and antioxidant rescue in MTPAP-deficient cells

   PMID:24651433

   Open questions at the time

   • Single lab
   • Mechanistic link between mitochondrial polyadenylation defect and nuclear DSB repair not fully resolved
4. 2019 Medium

   Whether multiple distinct missense mutations converge on the same molecular defect was answered by showing diverse pathogenic alleles shorten mitochondrial poly(A) tails and alter mitochondrial protein synthesis.

   Evidence Mitochondrial poly(A) tail length analysis and de novo mitochondrial protein synthesis assays in patient fibroblasts

   PMID:31779033

   Open questions at the time

   • Single lab
   • Transcript-specific consequences of tail shortening not delineated

• How shortened mitochondrial poly(A) tails mechanistically produce ROS dysregulation and neurodegeneration in SPAX4 remains unresolved.
• No causal chain established from poly(A) defect to neuronal pathology
• Transcript-level selectivity of MTPAP in vivo unknown